[go: up one dir, main page]

MEP36508A - Triazolopyrazine derivatives useful as anti-cancer agents - Google Patents

Triazolopyrazine derivatives useful as anti-cancer agents

Info

Publication number
MEP36508A
MEP36508A MEP-365/08A MEP36508A MEP36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A
Authority
ME
Montenegro
Prior art keywords
cancer agents
derivatives useful
triazolopyrazine derivatives
compounds
formula
Prior art date
Application number
MEP-365/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MEP36508A publication Critical patent/MEP36508A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-365/08A 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents MEP36508A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (fr) 2006-05-11 2007-04-30 Dérivés de triazolopyrazine utiles en tant qu'agents anti-cancereux

Publications (1)

Publication Number Publication Date
MEP36508A true MEP36508A (en) 2011-02-10

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-365/08A MEP36508A (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Country Status (32)

Country Link
US (2) US7732604B2 (fr)
EP (1) EP2018383B1 (fr)
JP (1) JP4377962B2 (fr)
KR (1) KR101099161B1 (fr)
CN (1) CN101443331A (fr)
AP (1) AP2008004674A0 (fr)
AR (1) AR060994A1 (fr)
AT (1) ATE532785T1 (fr)
AU (1) AU2007251283A1 (fr)
BR (1) BRPI0711809A2 (fr)
CA (1) CA2651363C (fr)
CR (1) CR10383A (fr)
EA (1) EA016204B1 (fr)
EC (1) ECSP088871A (fr)
ES (1) ES2376913T3 (fr)
GE (1) GEP20115174B (fr)
GT (1) GT200700039A (fr)
HN (1) HN2007015177A (fr)
IL (1) IL194813A0 (fr)
MA (1) MA30411B1 (fr)
ME (1) MEP36508A (fr)
MX (1) MX2008014399A (fr)
NL (1) NL2000613C2 (fr)
NO (1) NO20085060L (fr)
NZ (1) NZ572361A (fr)
PE (1) PE20080067A1 (fr)
RS (1) RS20080533A (fr)
TN (1) TNSN08445A1 (fr)
TW (1) TWI346115B (fr)
UY (1) UY30334A1 (fr)
WO (1) WO2007132308A1 (fr)
ZA (1) ZA200809020B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2253618A1 (fr) * 2008-02-27 2010-11-24 Takeda Pharmaceutical Company Limited Composé contenant un cycle aromatique à 6 chaînons
PE20091468A1 (es) * 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
EP2247185B1 (fr) * 2008-03-03 2014-04-16 Tiger Pharmatech Inhibiteurs de la tyrosine kinase
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
US20110130384A1 (en) * 2008-06-25 2011-06-02 Takeda Pharmaceutical Company Limited Amide compound
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
EP2356116A1 (fr) * 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
AU2009325072A1 (en) 2008-12-12 2011-06-30 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
MX2011006682A (es) 2008-12-22 2011-07-13 Merck Patent Gmbh Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
HRP20130986T1 (hr) * 2009-05-28 2013-11-22 Vertex Pharmaceuticals Incorporated Aminopirazol triazolotiadiazol inhibitori c-met protein kinaze
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
ES2927146T3 (es) 2009-12-31 2022-11-02 Hutchison Medipharma Ltd Ciertas triazolopirazinas, composiciones de estas y sus métodos de empleo
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
EP2588107A1 (fr) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2710003A1 (fr) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
WO2013151913A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Combinaisons d'inhibiteurs de tyrosine kinase et leur utilisation
CN107312009B (zh) * 2013-04-17 2022-09-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
ES2675355T3 (es) * 2013-09-30 2018-07-10 Korea Research Institute Of Chemical Technology Derivados de triazolopirazina como inhibidores de tirosina cinasa
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
IL305843B2 (en) 2015-07-20 2025-01-01 Genzyme Corp CSF-1R receptor antibodies
CN105272995B (zh) 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
CN109400613B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物富马酸盐的晶型、制备方法、组合物与应用
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
KR102519922B1 (ko) 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
WO2020124060A1 (fr) * 2018-12-14 2020-06-18 Beta Pharma, Inc. Composés substitués par organophosphoré en tant qu'inhibiteurs de c-met et leurs utilisations thérapeutiques
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
WO2025098425A1 (fr) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 Procédé de préparation de modulateur du récepteur de la chimiokine et utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
CA2260058A1 (fr) 1996-07-13 1998-01-22 Kathryn Jane Smith Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
BR0014073A (pt) * 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapêuticos
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
US20130246300A1 (en) 2012-03-13 2013-09-19 American Express Travel Related Services Company, Inc. Systems and Methods for Tailoring Marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
HN2007015177A (es) 2010-06-09
IL194813A0 (en) 2009-08-03
US20100105656A1 (en) 2010-04-29
CR10383A (es) 2008-11-11
MX2008014399A (es) 2008-11-27
PE20080067A1 (es) 2008-03-10
CN101443331A (zh) 2009-05-27
TW200804384A (en) 2008-01-16
CA2651363A1 (fr) 2007-11-22
EP2018383A1 (fr) 2009-01-28
RS20080533A (sr) 2009-09-08
US20070265272A1 (en) 2007-11-15
JP2009536636A (ja) 2009-10-15
NZ572361A (en) 2012-02-24
ECSP088871A (es) 2008-12-30
ATE532785T1 (de) 2011-11-15
AU2007251283A1 (en) 2007-11-22
TNSN08445A1 (fr) 2010-04-14
ES2376913T3 (es) 2012-03-20
JP4377962B2 (ja) 2009-12-02
CA2651363C (fr) 2011-07-12
EA200870423A1 (ru) 2009-04-28
WO2007132308A1 (fr) 2007-11-22
AP2008004674A0 (en) 2008-12-31
NO20085060L (no) 2008-12-03
EA016204B1 (ru) 2012-03-30
US7732604B2 (en) 2010-06-08
GEP20115174B (en) 2011-03-10
GT200700039A (es) 2008-06-02
TWI346115B (en) 2011-08-01
KR20090006187A (ko) 2009-01-14
ZA200809020B (en) 2009-12-30
EP2018383B1 (fr) 2011-11-09
MA30411B1 (fr) 2009-05-04
AR060994A1 (es) 2008-07-30
KR101099161B1 (ko) 2011-12-27
UY30334A1 (es) 2008-01-02
NL2000613C2 (nl) 2007-11-20
BRPI0711809A2 (pt) 2011-12-06

Similar Documents

Publication Publication Date Title
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
MEP43308A (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200970156A1 (ru) Пиридизиноновые производные
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
HRP20050933A2 (en) Organic compounds
WO2008030744A3 (fr) Inhibiteurs de c-met et leurs utilisations
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
CY1112401T1 (el) Παραγωγα πυριδαζινης
EP2613782A4 (fr) Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2007140439A3 (fr) Nouveaux composés constituant des ligands de récepteurs cannabinoïdes et utilisations de ces composés
EA200870282A1 (ru) Производные амина
UY30407A1 (es) Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones.
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
WO2009055629A3 (fr) Antagonistes trpv1